Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure

Abstract Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modula...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2016-01, Vol.203, p.909-915
Main Authors: Lopatin, Yuri M, Rosano, Giuseppe M.C, Fragasso, Gabriele, Lopaschuk, Gary D, Seferovic, Petar M, Gowdak, Luis Henrique W, Vinereanu, Dragos, Hamid, Magdy Abdel, Jourdain, Patrick, Ponikowski, Piotr
Format: Article
Language:English
Subjects:
Cardiac energy metabolism
Cardiovascular
Energy Metabolism
Heart failure
Heart Failure - drug therapy
Heart Failure - metabolism
Humans
Myocardium - metabolism
Prognosis
Treatment Outcome
Trimetazidine
Trimetazidine - pharmacokinetics
Vasodilator Agents - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2015.11.060